 I. To explore the association of response to treatment to the molecular phenotype of the tumor. Phase II II. Determine whether OSI-774 erlotinib and CCI-779 temsirolimus inhibits EGFR and mTOR and the PI3K-AKT-mTOR and RAS-ERK signaling pathways in tumor specimens taken from malignant glioma patients undergoing surgery. Phase II III. Tumor concentration of OSI-774 erlotinib and CCI-779 temsirolimus. Phase II 